AstraZeneca Withdraws Covid-19 Vaccine

AstraZeneca begins to withdraw its Covid-19 vaccine which could trigger death in some cases. The company is being sued

KRISTIAN OKA PRASETYADI

Vaccinators prepare the AstraZeneca brand Covid-19 vaccine in the atrium of the Manado Town Square 3 mall, Manado, North Sulawesi, on Thursday (13/1/2022).

LONDON, WEDNESDAY-Giants pharmacy UK-Sweden, AstraZeneca, withdraw vaccines covid-19 made by them. The company argued that there was an excess supply of the Covid-19 vaccine. The withdrawal was made after AstraZeneca admitted that their vaccine triggered side effects that could result in death in some cases.

British media, The Telegraph, reported the withdrawal on Tuesday (7/5/2024) evening London time or early Wednesday morning WIB. Withdrawal starts from European Union members. After that, withdrawals were also carried out in various countries.

Also read: AstraZeneca Not Withdrawn, People Asked to Choose Locally Produced Vaccines

The withdrawal notification was submitted to the authorities on Sunday (5/5/2024) and began on Tuesday. The withdrawal of the vaccine called Vaxzevria will be carried out in stages over the next few months.

In a statement quoted by Reuters, AstraZeneca cited oversupply as the reason for the withdrawal. Various vaccines have been continuously developed since the Covid-19 pandemic, resulting in a decreasing demand for Vaxzevria. On the other hand, AstraZeneca is no longer producing or distributing new packages of Vaxzevria.

ASTRAZENECA

effectiveness level of the AstraZeneca vaccine and the mRNA vaccine

Before the recall, AstraZeneca admitted Vaxzevria triggers blood clots or thrombocytopenia syndrome (TTS). In some cases, the side effects of the vaccine made by AstraZeneca can cause death. Now, the company is being sued.

The AstraZeneca Covid-19 vaccine is among those used in Indonesia. The Indonesian Food and Drug Authority (BPOM) stated that Vaxzevria is no longer in use or circulation in Indonesia. BPOM also stated that until April 2024, there have been no reports of blood clotting disorders associated with Vaxzevria in Indonesia.

Also read: AstraZeneca denies reports about the efficacy of their vaccine in the elderly

The World Health Organization (WHO) mentions that the incidence of thrombosis with thrombocytopenia syndrome (TTS) related to Vaxzevria is less than one case in 10,000. If it occurs, TTS is recorded within a period of 4 to 42 days after vaccination.

The Indonesian Food and Drug Authority (BPOM) and related institutions continue to monitor the safety of vaccines and any adverse events following immunization (AEFI) issue. BPOM also urges the public to immediately report any AEFI incidents. (REUTERS)